NICE end of life guidelines will not benefit people with dementia
Alzheimer’s Society comment on new guidelines issued by the National Institute for Health and Clinical Excellence (NICE) on life-extending treatments for people who are terminally ill and not expected
'End of life treatment is extremely important for all people with a terminal disease. 1 in 3 people over 65 will die with dementia; it is unreasonable that these people will not benefit from NICE's flexibility.
Whilst it is good that NICE is adopting some flexibility, NICE's entire remit needs to be reviewed. Everyone with a terminal condition deserves the best treatment and care available to them. It needs to be about quality care, not just extending life. People with Alzheimer's disease are still being denied access to the only drug treatments available to them.'
Neil Hunt
Chief Executive
Alzheimer's Society
Similar entries
- Alzheimer's drugs hope as NICE appeal denied
- Alzheimer's drugs decision based on flawed calculations
- Alzheimer's Society comment on new research into the use of quality adjusted life year
- Alzheimer's Society condemns putting costs ahead of care
- Alzheimer's Society comment on new data observing the cost effectiveness of Aricept (donepezil)
- NHS end-of-life drugs rule change
- Update on NICE appraisal of drugs for Alzheimer's disease following Court of Appeal ruling
- Patients will be able to pay privately for medicines while still receiving NHS care, ministers confirmed
- Alzheimer's drugs appeal victory
- Osteoporosis treatments denied unless condition worsens
